Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Brii Biosciences Announces Licensing Agreement with Joincare Group for BRII-693
Details : Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China.
Product Name : QPX9003
Product Type : Antibiotic
Upfront Cash : Undisclosed
July 03, 2025
Lead Product(s) : BRII-693
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Brii Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
